TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis C$15.08 +0.36 (+2.45%) As of 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsInsider TradesNews and TrendsOwnership About Fennec Pharmaceuticals Stock (TSE:FRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$15.08▼C$15.0850-Day RangeC$13.85▼C$17.6352-Week RangeC$7.59▼C$17.64Volume100 shsAverage Volume1,233 shsMarket CapitalizationC$528.81 millionP/E RatioN/ADividend Yield2.02%Price TargetN/AConsensus RatingStrong Buy Company Overview Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Read More Fennec Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreFRX MarketRank™: Fennec Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.0 / 5Analyst RatingStrong Buy Amount of Analyst CoverageFennec Pharmaceuticals has received no research coverage in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -125.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -125.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFennec Pharmaceuticals has a P/B Ratio of 12.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for FRX. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldFennec Pharmaceuticals pays a meaningful dividend of 2.02%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth.Read more about Fennec Pharmaceuticals' dividend. News and Social Media0.9 / 5News SentimentN/A News SentimentFennec Pharmaceuticals has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fennec Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$1,982,976.00 in company stock.Percentage Held by Insiders16.20% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.39% of the stock of Fennec Pharmaceuticals is held by institutions.Read more about Fennec Pharmaceuticals' insider trading history. Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FRX Stock News HeadlinesHC Wainwright Analysts Reduce Earnings Estimates for TSE:FRXSeptember 12, 2026 | americanbankingnews.comFennec Pharmaceuticals (TSE:FRX) Insider Sells C$206,160.00 in StockSeptember 9, 2026 | insidertrades.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.September 17 at 1:00 AM | Reagan Gold Group (Ad)Robert Christopher Andrade Sells 106,844 Shares of Fennec Pharmaceuticals (TSE:FRX) StockAugust 29, 2026 | insidertrades.comFennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings BeatAugust 11, 2026 | finance.yahoo.comFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026August 5, 2026 | markets.businessinsider.comFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 22, 2026 | financialpost.comFFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 15, 2026 | financialpost.comFSee More Headlines FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed this year? Fennec Pharmaceuticals' stock was trading at C$10.60 at the beginning of the year. Since then, FRX stock has increased by 42.3% and is now trading at C$15.08. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc. (TSE:FRX) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative net margin of 6.21% and a negative trailing twelve-month return on equity of 13.34%. Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' top institutional investors include Cornerstone Capital Inc. (0.30%). Insiders that own company stock include Rostislav Christov Raykov, Southpoint Capital Advisors Lp, Robert Christopher Andrade, Chris Anigeron Rallis, Pierre Sayad, Adrian J Haigh, Khalid Islam and Jeffrey Hackman. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray Brands (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Adherex Technologies (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS). Company Calendar Last Earnings11/07/2024Today9/17/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:FRX CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.12) Trailing P/E RatioN/A Forward P/E Ratio24.98 P/E GrowthN/ANet Income-C$800.44 thousand Net Margins-6.21% Pretax MarginN/A Return on Equity-13.34% Return on Assets8.88% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio10.17 Sales & Book Value Annual SalesC$59.22 million Price / Sales8.93 Cash FlowC$1.29 per share Price / Cash Flow11.66 Book ValueC$1.23 per share Price / Book12.28Miscellaneous Outstanding Shares35,067,000Free FloatN/AMarket CapC$528.81 million OptionableNot Optionable Beta3.72 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (TSE:FRX) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
